Medtronic stock analysis
Want to see MDT full AI Analyst Report?
Medtronic (MDT) Stock Price & Analysis
MDT Stock Chart & Stats
- Day’s Range
- $101.41 - $103.34
- 52-Week Range
- $73.31 - $106.33
- Previous Close
- $100.99
- Volume
- N/A
- Average Volume (3M)
- 22.19M
- Market Cap
- $131.58B
- Enterprise Value
- $129.69B
- Total Cash (Recent Filing)
- $8.82B
- Total Debt (Recent Filing)
- $28.15B
- Price to Earnings (P/E)
- 25.1
- Beta
- 0.29
- Next Earnings
- Nov 24, 2026 (Est.)
- EPS Estimate
- 1.33
- Last Dividend Ex-Date
- Sep 25, 2026
- Dividend Yield
- 2.78%
Bulls Say, Bears Say
Bulls Say
Broad-based Portfolio Growth
Growth across multiple operating units, regions and procedure volumes reduces reliance on any single therapy or market. This breadth supports more durable revenue expansion, gives successful products room to scale, and strengthens Medtronic’s ability to sustain performance through differing healthcare demand cycles.
Strong Cash Generation And Margins
Improving operating profitability alongside rising free cash flow gives Medtronic meaningful internal funding capacity. Strong cash generation can support research, acquisitions, debt service and shareholder returns, while the margin improvement indicates that recent growth is translating into better earnings quality.
Portfolio Simplification And Strategic Focus
Separating MiniMed and simplifying the product portfolio should allow management to focus resources on core cardiovascular, neuroscience and surgical platforms. SKU rationalization can also reduce complexity and improve execution, creating a clearer strategic base for innovation and operating leverage.
Bears Say
Elevated Debt And Leverage
Although equity supports a moderate leverage profile, the elevated absolute debt balance can reduce financial flexibility if growth slows or capital costs rise. Debt service and refinancing requirements may compete with investment in innovation, acquisitions and shareholder distributions over the medium term.
Neuromodulation Market Softness
Weakness in spinal cord stimulation and replacement demand creates a persistent drag within the neuroscience portfolio. If these conditions continue, they could limit segment growth, dilute the benefit of stronger newer products, and require additional investment to restore momentum and defend market position.
Structural Heart Underperformance
Low-single-digit Structural Heart growth indicates that an important cardiovascular category is expanding more slowly than several of Medtronic’s faster-growing businesses. Stable procedure volumes and slower portfolio momentum could constrain mix improvement and limit the segment’s contribution to overall growth.
Medtronic News
MDT FAQ
What was Medtronic’s price range in the past 12 months?
What is Medtronic’s market cap?
When is Medtronic’s upcoming earnings report date?
How were Medtronic’s earnings last quarter?
Is Medtronic overvalued?
Does Medtronic pay dividends?
What is Medtronic’s EPS estimate?
How many shares outstanding does Medtronic have?
What happened to Medtronic’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medtronic?
What is the TipRanks Smart Score and how is it calculated?
Medtronic Stock Smart Score
Company Description
Medtronic
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha
- Employees
- 95,000
- Website
- www.medtronic.com
- Address
- Building Two, Parkmore Business Park West, Galway, GA, H91 4K49, IE
Medtronic (MDT) Earnings & Revenues
MDT Company Deck
MDT Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Medtronic reported broad-based revenue and earnings outperformance, significant growth in Cardiac Ablation Solutions, continued momentum in CRM, CST, Surgical, Pelvic Health and Diabetes, improved operating metrics, stronger cash conversion and raised fiscal 2027 guidance. The principal challenges were business-mix pressure on gross margin, neuromodulation softness, low-single-digit Structural Heart growth, expected moderation in some growth rates, and foreign exchange and tariff headwinds.
View all MDT earnings summariesMDT Net sales Breakdown
- 36.56% Cardiovascular
- 29.06% Neuroscience
- 26.01% Medical Surgical
- 7.69% Diabetes
- 0.68% Other operating segment
MDT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 6 | 1 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 12 | 0 | 0 |













